penberol and Ovarian-Neoplasms

The authors report their results of treatment in patients with ovarian carcinoma (stages III and IV, FIGO classification) with the cytostatic Penberol (cis-beta-4-pentoxybenzoyl-beta-bromoacrylic acid), synthesized at the Research Institute for Pharmacy and Biochemistry in Prague. The present communication links on the paper published in 1980. Out of 20 patients treated with Penberol, 11 have responded by a complete remission persisting for 8-55 months; in five of them the remission has not finished as yet. Both in the experiment and in the clinic the behavior of Penberol differs from that of classical cytostatics, and the observations evaluated so far attest to antitumor activity based on inhibition of the cell energetic metabolism.

Topics: Acrylates; Adenocarcinoma, Mucinous; Adult; Aged; Antineoplastic Agents; Drug Evaluation; Female; Humans; Middle Aged; Ovarian Neoplasms

The authors present results of a preliminary study on the efficiency of the preparation Penberol [VUFB Prague (cis-beta-4-pentoxy-benzoyl-beta-bromoacrylic acid) CHECO protocol number 4] in the ovarian carcinoma of the stage III and IV (FIGO) in which the drug was used after the failure of the first choice chemotherapy. Out of ten patients, complete regression of the lesions was achieved in 7 patients, only in two cases the regression was lower than 50% and in one case a progression was encountered during the therapy. The median of the duration of non-completed remission is 15+ months. As to the side effects, in half cases the dose of the preparation was reduced by 1/3 because of diarrhea induced by irritating action of the drug on the intestinal wall. No other side effects of the therapy were observed.

Topics: Acrylates; Adult; Aged; Antineoplastic Agents; Female; Humans; Middle Aged; Ovarian Neoplasms; Time Factors